Ownership history in MARSHALL WACE, LLP · 8 quarters on record
This page tracks every 13F SEC filing in which MARSHALL WACE, LLP reported a position in ADC THERAPEUTICS (ADCT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 159,993 | -83,250 | -34.2% | 0.00% | $640K | $4.00 |
| 2024 Q1 | ADDED | 243,243 | +221,395 | +1013.3% | 0.00% | $1.1M | $4.49 |
| 2023 Q4 | REDUCED | 21,848 | -416,825 | -95.0% | 0.00% | $36K | $1.66 |
| 2023 Q3 | ADDED | 438,673 | +73,615 | +20.2% | 0.00% | $395K | $0.90 |
| 2023 Q2 | ADDED | 365,058 | +207,379 | +131.5% | 0.00% | $785K | $2.15 |
| 2023 Q1 | ADDED | 157,679 | +98,112 | +164.7% | 0.00% | $307K | $1.95 |
| 2020 Q4 | REDUCED | 59,567 | -136,085 | -69.6% | 0.01% | $1.9M | $32.01 |
| 2020 Q3 | INITIATED | 195,652 | — | — | 0.04% | $6.5M | $32.99 |
As of 2025 Q4 — sorted by position size